SOLV - Solventum Corporation

Solventum Corporation provides healthcare technology products including 3M-branded medical tapes, wound care dressings, dental restoratives, and health information systems software, spun off from 3M in 2024. The company sells primarily to hospitals, dental practices, and health systems through a B2B model with a mix of consumable product sales and software subscription contracts. Solventum generates approximately $8B in annual revenue with significant exposure across North America, Europe, and Asia-Pacific. The business operates across four segments: MedSurg, Dental Solutions, Health Information Systems, and Purification & Filtration.

Past Year Trends

• Solventum divested its Purification & Filtration business to Thermo Fisher Scientific for $4.1 billion (net proceeds $3.4 billion) in September 2025, using the proceeds to cut total debt by 35.5% from $7.81 billion to $5.04 billion within the fiscal year. (Bullish)
• Adjusted operating margin compressed 150 basis points year-over-year to 20.5% in FY2025, with full-year free cash flow turning negative at -$10 million due to cumulative transformation program implementation costs estimated at $500 million. (Bearish)
• Full-year FY2025 revenue grew only 0.9% to $8.325 billion despite 3–5.5% organic growth across all four segments, as the Purification & Filtration divestiture removed a high-growth contributor and adjusted diluted EPS declined 8.8% YoY to $6.11. (Bearish)

Next Year Trends

• The $500 million 'Transform for the Future' cost savings program is expected to drive free cash flow from -$10 million in FY2025 to approximately $200 million in FY2026, with the $1 billion share repurchase program adding incremental shareholder return if targets are met. (Bullish)
• The December 2025 acquisition of Acera Surgical ($725 million upfront, $850 million total potential) targets the $900 million U.S. synthetic tissue matrices market with Restrata® regenerative wound care products but will be slightly dilutive to adjusted EPS in 2026, with accretion not expected until 2027. (Bearish)
• U.S. tariff exposure is projected to create approximately 40 basis points of gross margin headwind in FY2026, pressuring the company's 2026 adjusted EPS guidance of $6.40–$6.60, which is already below FY2024's $6.70 adjusted EPS. (Bearish)

Red Flags

No severe red flags identified as of August 2025.